<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1307">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567810</url>
  </required_header>
  <id_info>
    <org_study_id>CVR001</org_study_id>
    <nct_id>NCT04567810</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)</brief_title>
  <official_title>A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of Part 1 (Single Ascending Dose) is to assess the safety and
      tolerability of anti-SARS-CoV-2 IgY when given as single-ascending doses administered
      intranasally to healthy participants.

      The primary objective of Part 2 (Multiple Dose) is to assess the safety and tolerability of
      anti-SARS-CoV-2 IgY when given as multiple doses administered intranasally to healthy
      participants. A secondary objective is to assess the pharmacokinetics of anti-SARS-CoV-2 IgY
      when given as multiple doses administered intranasally to healthy participants.

      Safety will be evaluated using adverse event (AE), physical examination (including vital
      signs), electrocardiogram, and clinical laboratory data. Pharmacokinetics will be evaluated
      by serum anti-SARS-CoV-2 IgY concentration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>up to 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vital Sign Findings Reported as TEAEs</measure>
    <time_frame>up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Findings in Physical Examinations</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Clinically significant in the judgement of the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes From Baseline in ECG Data</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Clinically significant in the judgement of the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Clinically significant in the judgement of the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Presence of Serum anti-SARS-CoV-2 IgY</measure>
    <time_frame>up to 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Part A: 2 mg preparation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single 2 mg dose of anti-SARS-CoV-2 IgY.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 4 mg preparation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single 4 mg dose of anti-SARS-CoV-2 IgY.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 8 mg preparation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single 8 mg dose of anti-SARS-CoV-2 IgY.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: placebo preparation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo matching anti-SARS-CoV-2 IgY.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: 6 mg total daily dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a 2 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: 12 mg total daily dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a 4 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: 24 mg total daily dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a 8 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: 0 mg total daily dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo matching anti-SARS-CoV-2 IgY three times daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-SARS-CoV-2 IgY</intervention_name>
    <description>anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.</description>
    <arm_group_label>Part A: 2 mg preparation</arm_group_label>
    <arm_group_label>Part A: 4 mg preparation</arm_group_label>
    <arm_group_label>Part A: 8 mg preparation</arm_group_label>
    <arm_group_label>Part B: 12 mg total daily dose</arm_group_label>
    <arm_group_label>Part B: 24 mg total daily dose</arm_group_label>
    <arm_group_label>Part B: 6 mg total daily dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.</description>
    <arm_group_label>Part A: placebo preparation</arm_group_label>
    <arm_group_label>Part B: 0 mg total daily dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or non-pregnant, non-lactating females

          -  Body weight of at least 50 kg

          -  Good state of health (mentally and physically)

          -  Must agree to use of highly effective method of contraception

        Exclusion Criteria:

          -  Received other investigational drug within the last 30 days prior to screening

          -  History of drug or alcohol abuse in the past 2 years (&gt;21 units of alcohol per week
             for males and &gt;14 units of alcohol per week for females)

          -  Current smoker / e-smoker

          -  Abnormal kidney function

          -  Abnormal liver function

          -  Positive for hepatitis B or C infection

          -  Positive for HIV infection

          -  Positive for SARS-CoV-2 infection

          -  History of egg allergy

          -  Abnormal cardiac function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daria Mochly-Rosen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michaela Lucas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linear Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Linear Clinical Research - Harry Perkins Research Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Team</last_name>
      <phone>+61 300 546327</phone>
      <email>contactus@linear.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

